
DVN · NYSE
The supplied consensus is Buy across 23 analysts, with a mean price target of $60; low and high targets are unavailable, so the breadth of the formal range cannot be measured. The named targets cluster from UBS at $58 to Raymond James at $66, making Raymond James the most bullish and UBS the least bullish among specifically identified firms. Other services cite materially different averages, including $52.61, $53.94, $58.81 and $61.28. The evidence describes revisions as mixed but modestly downward overall, citing UBS's cut to $58 alongside several increases between $54 and $68. No dated revision during this supplied week is identified. The substantive disagreement centers on earnings growth versus negative free cash flow and valuation dispersion.
| Firm | Analyst | Rating | Price Target | Upside | Date | Source |
|---|---|---|---|---|---|---|
| Raymond James | — | $66 | +32.7% | Jun 15, 2026 | Open the report this row came from |